Document:

PROMISSORY
NOTE

 

	$200,000
    US Currency	March
    3, 2015

 

FOR
VALUE RECEIVED, American Brewing Company, Inc. (hereinafter referred to as the “Maker”) promises to pay to the order
of NUWA Group, LLC, (“Holder”), in lawful money of the United States of America, the principal sum of up to Two Hundred
Thousand Dollars ($200,000), or so much thereof as may be hereafter disbursed, together with interest thereon from date set forth
above at the rate of Ten Percent (10%) percent per annum, simple interest, until maturity.

 

SECTION
ONE - TERMS

 

The
funding and repayment terms of this note shall be as follows:

 

a)       An
initial amount of Thirty Eight Thousand, Five Hundred Dollars ($38,500) shall be funded upon execution of this Note. The remaining
One Hundred Sixty One Thousand, Five Hundred Dollars ($161,500) shall be funded at the option of the Maker upon the closing of
the asset purchase transaction between B&R Liquid Adventure, LLC and Maker.

 

b)       The
entire principal amount of this Note shall be due and payable on March 3, 2020, which is five years from the Effective Date of
this Promissory Note.

 

c)       Interest
shall accrue and be due and payable each calendar quarter beginning on June 30, 2015, at the interest rate of 10% per annum. Each
quarterly interest payment shall be due within 15 business days of the end of each quarter, and shall be paid by check or wire
transfer to “NUWA Group, LLC”. The indebtedness evidenced by this Note, including all principal and accrued interest,
may be prepaid in whole or in part at any time without penalty or premium.

 

d)       If
Maker closes a round of funding in an amount of Two Million Dollars ($2,000,000) or more during the term of this Note, the outstanding
principal and interest of the Note shall be paid out of the proceeds of such funding.

 

SECTION
TWO - USE OF FUNDS

 

The
funds loaned under this Promissory Note will be immediately deposited in to the Makers bank account to be used for Maker’s
purchase of B&R Liquid Adventure, LLC.

 

SECTION
THREE - REMEDIES

 

In
the event any payment is not made within fifteen (15) days of its due date, the Maker shall pay a late fee of five (5.0%) percent
of the amount of the payment, provided that only one (1) such late charge may be collected on any particular payment however long
that payment shall remain past due.

 

Presentment
for payment, demand, protest and notice of demand, notice of dishonor and notice of nonpayment and all other notices are
hereby waived by Maker. No extension of the time for the payment of this Note or any installment due hereunder, made by
agreement with any person now or hereafter liable for the payment of this Note shall operate to release, discharge, modify,
change or affect the original liability of the Maker under this Note, either in whole or in part, unless the Holder agrees
otherwise in writing. This Note may not be changed orally, but only by an agreement in writing signed by the party against
whom enforcement of any waiver, change, modification or discharge is sought.

 

    	 	 	 

     

    

 

SECTION
FOUR - RISKS

 

IN
MAKING A DECISION TO LEND FUNDS SUBSCRIBERS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE NOTE INSTRUMENT,
INCLUDING THE MERITS AND RISKS INVOLVED. A LOAN IN A NEW COMPANY IS CONSIDERED TO BE A HIGH RISK.

 

The
Holder has such knowledge and experience in financial and business matters that the Holder is capable of evaluating the merits
and risks of this Promissory Note and of making an informed financial decision, and does not require a Company representative
in evaluating the merits and risks, or has relied upon the advice of a Company representative.

 

The
Holder has been given the opportunity to ask question of and to receive answers from persons acting on the Company’s behalf
concerning the terms and conditions of this transaction and also has been given the opportunity to obtain any additional information
which the Company possesses or can acquire without unreasonable effort or expense. As a result, Holder is cognizant of the financial
condition, capitalization, use of proceeds from this financing and the operations and financial condition of Company, has available
full information concerning their affairs and has been able to evaluate the merits and risks of the Promissory Note.

 

SECTION
FIVE - NOTICE

 

All
notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery
to the Party to be notified, (b) when sent by confirmed facsimile if sent during normal business hours of the recipient, if not,
then on the next business day, or (c) one (1) day after deposit with a nationally recognized overnight courier, specifying next
day delivery, with written verification of receipt.

 

SECTION
SIX - OTHER TERMS

 

Maker
hereby waives and renounces for itself, its heirs, successors and assigns, all rights to the benefits of any statute of limitations,
any moratorium, reinstatement, marshaling, forbearance, valuation, stay, extension, redemption, appraisement and exemption now
provided, or which may hereafter by provided, by the Constitution and laws of the United States of America and of any state thereof,
against the enforcement and collection of the obligations evidenced by this Note.

 

This
Note may not be assigned by either party hereto without the prior written consent of the other.

 

This
Note shall be governed by the laws of the State of Washington, United States of America.

 

In
witness whereof, the Parties have executed this Promissory Note as of the date set forth above

 

	American
    Brewing Company, Inc.	 	NUWA
    Group, LLC
	 	 	 	 	 
	Signed:	 /s/
    Neil Fallon 	 	Signed:	 /s/
    Kevin Fickle
	By:	 Neil Fallon	 	By:	Kevin Fickle
	Its:	 President	 	Its:	Managing
Memberex10-1.htm

Exhibit 10.1 

 

 

December 14, 2016

 

 

Dr. Chris Xu

c./o Cesca Therapeutics Inc.

2711 Citrus Road

Rancho Cordva, CA  95742

 

 

Re:      Terms of Employment as interim Chief Executive Officer

 

 

Dear Chris:

 

On behalf of the Compensation Committee of the Board of Directors (the “Board”) of Cesca Therapeutics, (the “Company”), we are pleased to confirm for you, the following terms of employment (the “Terms”) as the Company’s Chief Executive Officer, on an interim basis. The Terms are effective retroactively to November 4, 2016:

 

1.        Position.

 

You will serve as the interim Chief Executive Officer of the Company. Your place of employment is the Company’s office in Rancho Cordova, CA. Your responsibilities in this position include managing the day-to-day operations of the Company and reporting to the Board. 

 

2.        Compensation.

 

Your base salary will be at the rate of $425,000 per year, less payroll deductions and all required withholdings. You will be paid on the Company’s regularly scheduled pay dates. 

 

You are eligible to earn a bonus compensation of up to 60% of your base salary (the “Bonus”) for your performance in 2017. Any earned Bonus is payable in cash or in shares of the Company’s common stock, subject to the Board’s discretion. Bonus determination will be based on the corporate/personal goals that will be mutually determined by you and the Compensation Committee at the next in person meeting of the Board of Directors.

 

Additionally, you are eligible to participate in any of the Company’s plans for its employees.

 

 

 

 

  

3.        Stock Grant.

 

You will be granted options to purchase up to 50,000 shares of the Company Common Stock (“Options”) under the Company’s Stock Incentive Plan (the “Plan”). The Board may, in its absolute discretion, choose to grant to you additional options in the future. The Options are subject to the terms of the Plan, and will in five equal installments: 20% upon signing of this Letter Agreement, 20% on February 4, 2017, 20% on May 4, 2017, 20% on August 4, 2017, and 20% on November 4, 2017, assuming remain in continuous and uninterrupted employment with the Company. 

 

4.        Confidential Information and Non-Solicitation Agreement.

 

Like all Company employees, you will be required, as a condition of your employment, to abide by Company rules and policies, and sign any personnel agreement, concerning the handling of Confidential Information and Non-Solicitation, which, among other things, prohibits the unauthorized use or disclosure of the Company’s proprietary and confidential information and the unauthorized disclosure or use of any third party proprietary and confidential information. 

 

You further agree that you will not bring onto Company premises any unpublished documents or property belonging to any former employer or other person to whom you have an obligation of confidentiality. In addition, as a condition of employment, you agree that you will not assist any person or organization in competing with the Company, in preparing to compete with the Company or in hiring any employees of the Company.

 

Throughout the duration of your employment, you agree to disclose to the Company in writing, any continuing outside working relationships with other customers or entities with whom you are working or will work (whether or not for compensation), as well as any potential conflicts of interest, sources of income or other business endeavors 

 

5.        At-Will Employment.

 

Your employment with the Company will continue to be “at-will.” This means that either you or the Company may terminate your employment relationship at any time, with or without notice, and with or without cause. By accepting the role of interim CEO, you confirm you understand and agree, that this at-will relationship cannot be changed or retracted, either orally or in writing, or by any policy or conduct, unless you receive a document expressly stating that your employment is no longer at-will, which is signed both by you and the Chair of the Compensation Committee.

 

In addition, you acknowledge that at the Board’s discretion, the Company will commence a formal search for a permanent CEO and you agree to assist the Company in that search.

 

 

 

 

  

6.        Termination

 

You acknowledge that as interim CEO, you will not be entitled to any salary continuation or severance payments in the event of Termination, be it for change of control, with cause, without cause, constructive terminated, or if you voluntarily resign.

 

7.        Additional Information.

 

This letter and the agreements for the Options, Confidential Information and Anti-Solicitation, contain all of the terms of your employment with the Company and supersede any prior understandings or agreements, whether oral or written, between you and the Company. This letter may not be amended or modified except by an express written agreement signed by you and the Chairman of the Compensation Committee.

 

Upon acceptance of this letter, please sign and return it to Mike Bruch, the Company’s Chief Financial Officer, with a copy to the undersigned.

 

 

Sincerely,

 

 

 

/s/ Mahendra Rao, Ph.D.                               

Mahendra Rao, Ph.D.

Chairman, Compensation Committee

Board of Directors

 

 

 

Agreed and accepted as of:

Date: December 16, 2016

 

 

 

/s/ Chris Xu, Ph.D.                                         

Chris Xu, Ph.D.

 

 

Copy:      Mike Bruch

 Michael Rhein

 Vivian Liu

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}]]